MBX Biosciences has filed for an initial public offering with the SEC. The expected closing date and other details of the IPO have not been disclosed. However, the company has announced a placeholder of USD 100 million. The company expects to commence trading on the Nasdaq under the ticker symbol "MBX."

MBX plans to channel funds from the IPO toward its ongoing R&D activities, corporate functions, and potential business deals. The funds will also accelerate the progression of its lead program MBX 2109, a treatment for chronic hypoparathyroidism, through Phase II into Phase III studies and support other investigational programs, including MBX 1416 and MBX 4291.

MBX Biosciences is a biopharmaceutical company that uses its proprietary Precision Endocrine Peptide (PEP) to develop novel precision peptide therapies for endocrine and metabolic disorders. MBX's lead candidate, MBX 2109, is in Phase II development for chronic hypoparathyroidism. This long-acting parathyroid hormone peptide prodrug is designed for once-weekly dosing to simplify disease management. Other candidates include MBX 1416 for post-bariatric hypoglycemia and early-stage candidates such as MBX 4291 for obesity and other metabolic disorders.

Analyst QuickTake: On August 5, 2024, MBX raised USD 5 million in a Series C funding round led by Deep Track Capital, with participation from Driehaus Capital Management, Frazier Life Sciences, and OrbiMed, among other investors. The funds were expected to be used to support the expansion of MBX’s clinical development programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity.